home / stock / lixtw / lixtw news

LIXTW News and Press, Lixte Biotechnology Holdings Inc. Warrants From 02/26/24

Stock Information
Company Name: Lixte Biotechnology Holdings Inc. Warrants
Stock Symbol: LIXTW
Market: NASDAQ
Menu
LIXTW LIXTW Quote LIXTW Short LIXTW News LIXTW Articles LIXTW Message Board
Get LIXTW Alerts

News, Short Squeeze, Breakout and More Instantly...
LIXTW - LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”) today announced th...
LIXTW - First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-1...

LIXTW - LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunothe...

LIXTW - LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

Extension Agreement Follows Successful Two-Year Collaboration in Colon Cancer PASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW) announced that it has signed an agreement to expand its collaboration wit...
LIXTW - LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the ...

LIXTW - LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Biotechnology V eteran Bas van der Baan B rings P recision O ncology E xpertise ; Founder John S . Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, I...

LIXTW - LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A PASADENA, CA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( ...
LIXTW - LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

PASADENA, CA, July 20, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the closing of its previously announced registered direct offering of 583,334 shares of common stock (or comm...

LIXTW - LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

PASADENA, CA, July 18, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced it has entered into a securities purchase agreement with a single health-care focused, institutional investor for...

LIXTW - Preclinical Results of LIXTE Biotechnology's Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE's Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy

Results Provide Striking Molecular Evidence that I nhibiting PP2A with LB -100 Sensitizes Cancer Cells to Immunotherapy and Chemotherapy PASADENA, CA, July 17, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (&#x...
Previous 10 Next 10